

Date : 30<sup>th</sup> July, 2019.

To  
BSE Ltd.  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

Sub.: **Outcome of Board Meeting held today, i.e. 30<sup>th</sup> July, 2019 – Unaudited Results for the Quarter ended 30<sup>th</sup> June, 2019.**

Reg.: **Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.**

Dear Sir,

Kindly note that the Audit Committee have reviewed and the Board of directors of the Company have approved the unaudited financial results for the quarter ended on 30<sup>th</sup> June, 2019 during their respective meetings held today, i.e. on 30<sup>th</sup> July, 2019.


The unaudited financial results for the quarter from 1<sup>st</sup> April, 2019 to 30<sup>th</sup> June, 2019 duly signed in the format specified under clause 30(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, is enclosed.

Also enclosed alongwith is the limited audit review report of the auditors of the Company, on the unaudited financial results for the quarter ended on 30<sup>th</sup> June, 2019.

Kindly take on record the above and acknowledge.

Thanking you,

Yours faithfully,  
For Jenburkt Pharmaceuticals Ltd.,

  
(ASHISH SHAH)  
Company Secretary.

Encl.: As Stated Above.

**Statement of Unaudited Standalone Financial Results for the Quarter Ended on 30/06/2019**

Rs. In Lacs other than EPS

Sr. No.	Particulars	Quarter Ended				Year Ended
		30/06/2019	31/03/2019	30/06/2018	31/03/2019	
		Unaudited	Audited	Unaudited	Audited	
1	Revenue from Operations	2083.74	3512.59	2325.82	12264.43	
2	Other Income	123.80	93.24	90.53	340.97	
3	<b>Total income</b>	<b>2207.54</b>	<b>3605.83</b>	<b>2416.35</b>	<b>12605.40</b>	
4	<b>Expenses</b>					
	(a) Cost of Materials Consumed	239.98	233.92	248.96	1184.31	
	(b) Purchase of Stock-in-trade	644.05	780.01	568.74	2690.71	
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	-211.62	-59.71	-108.18	-249.39	
	(d) Employee benefit expenses	882.29	821.83	778.50	3120.49	
	(e) Finance Costs	6.74	9.62	8.99	38.59	
	(f) Depreciation and Amortisation Expense	52.84	35.16	31.62	135.30	
	(g) other expenses	591.00	845.78	577.37	3022.05	
	<b>Total Expenses</b>	<b>2205.28</b>	<b>2666.61</b>	<b>2106.00</b>	<b>9942.06</b>	
5	<b>Profit before exceptional items &amp; Tax</b>	<b>2.26</b>	<b>939.22</b>	<b>310.35</b>	<b>2663.34</b>	
6	<b>Exceptional Items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	
7	<b>Profit before tax</b>	<b>2.26</b>	<b>939.22</b>	<b>310.35</b>	<b>2663.34</b>	
8	<b>Tax Expense</b>					
	(i) Current Tax	0.00	252.00	105.00	752.00	
	(ii) Income Tax for previous years	0.00	0.00	-32.80	-37.52	
	(ii) Deferred Tax	-3.93	-2.23	-31.56	-30.92	
9	<b>Profit after tax for the period</b>	<b>6.19</b>	<b>689.45</b>	<b>269.71</b>	<b>1979.78</b>	
10	<b>Other Comprehensive Income</b>					
	(i) Items that will not be reclassified to profit or loss	9.41	-53.76	0.00	-44.97	
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	19.18	17.68	0.00	17.68	
	(iii) Items that will be reclassified to profit or loss	0.00	0.00	7.53	0.00	
	(iv) Income Tax relating to Items that will be reclassified to profit or loss	0.00	12.20	-12.11	0.00	
11	<b>Total Comprehensive Income for the period</b>	<b>34.78</b>	<b>665.57</b>	<b>265.13</b>	<b>1952.49</b>	
12	<b>Paid up Equity Share Capital (F.V. Rs.10/- each)</b>	<b>458.94</b>	<b>458.94</b>	<b>458.94</b>	<b>458.94</b>	
13	<b>Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted</b>	<b>0.13</b>	<b>15.02</b>	<b>5.88</b>	<b>43.14</b>	

**Notes:**

- The above statement of unaudited standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 30<sup>th</sup> July, 2019.
- The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- The figures of the previous year/period have been regrouped/rearranged to render them comparable with figures of the current period.

By order of the Board  
For Jenburkt Pharmaceuticals Ltd.


**CHAIRMAN AND MANAGING DIRECTOR**

Place : Mumbai

Date : 30<sup>th</sup> July, 2019

 Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai



# D.R.MEHTA & ASSOCIATES

(CHARTERED ACCOUNTANTS)

H-2, EVEREST BUILDING, 9<sup>TH</sup> FLOOR, TARDEO CIRCLE, MUMBAI - 400034

TEL: 23513758 / 23520330 FAX: 66607263, 9322508373

Email ID: [info@drmehta.in](mailto:info@drmehta.in), [vikram@drmehta.in](mailto:vikram@drmehta.in), [ashok@drmehta.in](mailto:ashok@drmehta.in)

Review Report to  
The Board of Directors

Jenburkt Pharmaceuticals Ltd.

We have reviewed the accompanying statement of unaudited financial results of JENBURKT PHARMACEUTICALS LTD for the period 1<sup>st</sup> April 2019 to 30<sup>th</sup> June 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For D.R.Mehta & Associates,  
(Chartered Accountants)  
(Firm Reg.No. 106207W)



Partner..

Chartered Accountants

(Ashok D Mehta)

(Membership Number - 101746)

UDIN : 19101746AAAABH4087

Place of signature: Mumbai

Date:- 30th July 2019.

